Publications by authors named "Suma Krishnan"

Claim this Profile
E
Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Study of Japanese Subjects With Dystrophic Epidermolysis Bullosa.
Ken Natsuga, Daisuke Tsuruta, Shota Takashima, Chiharu Tateishi, Masaaki Takatoku, Suma M Krishnan

J Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.
M Peter Marinkovich, Amy S Paller, Shireen V Guide, Mercedes E Gonzalez, Anne W Lucky, Suma M Krishnan

Am J Clin Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.
M Peter Marinkovich, Amy S Paller, Shireen V Guide, Mercedes E Gonzalez, Anne W Lucky, Suma M Krishnan

Am J Clin Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wound behavior in dystrophic epidermolysis bullosa: A retrospective natural history case series.
Tatum La, Hubert Chen, Shijie Chen, I Sinem Bagci, Kunju Sridhar, Suma Krishnan

J Am Acad Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa.
Arianna Tovar Vetencourt, Ibrahim Sayed-Ahmed, Jennifer Gomez, Hubert Chen, Brittani Agostini, Suma Krishnan

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Shireen V Guide, Mercedes E Gonzalez, I Sinem Bağcı, Brittani Agostini, Hubert Chen, Suma Krishnan

N Engl J Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
Irina Gurevich, Pooja Agarwal, PeiPei Zhang, John A Dolorito, Stacie Oliver, Suma M Krishnan

Nat Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of a Modified Herpes Simplex Virus Type 1 Vector Encoding Human TGM1 for the Treatment of Autosomal Recessive Congenital Ichthyosis.
John C Freedman, Trevor J Parry, Peipei Zhang, Avijit Majumdar, Suma Krishnan

J Invest Dermatol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts.
Velina S Atanasova, Rebecca J Russell, Timothy G Webster, Qingqing Cao, Pooja Agarwal, Suma Krishnan

J Invest Dermatol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study.
Samuel W Boellner, Jeffrey G Stark, Suma Krishnan, Yuxin Zhang

Clin Ther· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers.
Suma M Krishnan, Michael Pennick, Jeffrey G Stark

Clin Drug Investig· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Lenard A Adler, David W Goodman, Scott H Kollins, Richard H Weisler, Suma Krishnan

J Clin Psychiatry· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
Robert L Findling, Ann C Childress, Suma Krishnan, James J McGough

CNS Spectr· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.
Suma Krishnan, Yuxin Zhang

J Clin Pharmacol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
Suma M Krishnan, Jeffrey G Stark

Curr Med Res Opin· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
Joseph Biederman, Samuel W Boellner, Ann Childress, Frank A Lopez, Suma Krishnan

Biol Psychiatry· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies.
Suma Krishnan, Scott Montcrief

Basic Clin Pharmacol Toxicol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
Joseph Biederman, Suma Krishnan, Yuxin Zhang, James J McGough, Robert L Findling

Clin Ther· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes.
Suma Krishnan, Scott Moncrief

Drug Metab Dispos· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis